Considerations for statin therapy in patients with COVID-19.
Identifieur interne : 000066 ( PubMed/Curation ); précédent : 000065; suivant : 000067Considerations for statin therapy in patients with COVID-19.
Auteurs : Simin Dashti-Khavidaki [Iran] ; Hossein Khalili [Iran]Source :
- Pharmacotherapy [ 1875-9114 ] ; 2020.
Abstract
Current coronavirus pandemic named coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the third coronavirus outbreak during the current century after severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses.1 Acute respiratory distress syndrome (ARDS) is an immunopathologic event and main cause of death following COVID-19. The main mechanism of ARDS is uncontrolled systemic inflammatory response and cytokine storm following release of proinflammatory cytokines (such as interferons (IFN), interleukines (IL), tumor necrosis factor (TNF)-α) and chemokines.2-3 So, some Chinese researchers proposed or used anti-inflammatory agents in the treatment regimen of patients with COVID-19.3-4.
DOI: 10.1002/phar.2397
PubMed: 32267560
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000066
Links to Exploration step
pubmed:32267560Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Considerations for statin therapy in patients with COVID-19.</title>
<author><name sortKey="Dashti Khavidaki, Simin" sort="Dashti Khavidaki, Simin" uniqKey="Dashti Khavidaki S" first="Simin" last="Dashti-Khavidaki">Simin Dashti-Khavidaki</name>
<affiliation wicri:level="1"><nlm:affiliation>Professor of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation>
<country xml:lang="fr">Iran</country>
<wicri:regionArea>Professor of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Khalili, Hossein" sort="Khalili, Hossein" uniqKey="Khalili H" first="Hossein" last="Khalili">Hossein Khalili</name>
<affiliation wicri:level="1"><nlm:affiliation>Professor of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation>
<country xml:lang="fr">Iran</country>
<wicri:regionArea>Professor of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32267560</idno>
<idno type="pmid">32267560</idno>
<idno type="doi">10.1002/phar.2397</idno>
<idno type="wicri:Area/PubMed/Corpus">000066</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000066</idno>
<idno type="wicri:Area/PubMed/Curation">000066</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000066</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Considerations for statin therapy in patients with COVID-19.</title>
<author><name sortKey="Dashti Khavidaki, Simin" sort="Dashti Khavidaki, Simin" uniqKey="Dashti Khavidaki S" first="Simin" last="Dashti-Khavidaki">Simin Dashti-Khavidaki</name>
<affiliation wicri:level="1"><nlm:affiliation>Professor of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation>
<country xml:lang="fr">Iran</country>
<wicri:regionArea>Professor of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Khalili, Hossein" sort="Khalili, Hossein" uniqKey="Khalili H" first="Hossein" last="Khalili">Hossein Khalili</name>
<affiliation wicri:level="1"><nlm:affiliation>Professor of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation>
<country xml:lang="fr">Iran</country>
<wicri:regionArea>Professor of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Pharmacotherapy</title>
<idno type="eISSN">1875-9114</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Current coronavirus pandemic named coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the third coronavirus outbreak during the current century after severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses.<sup>1</sup>
Acute respiratory distress syndrome (ARDS) is an immunopathologic event and main cause of death following COVID-19. The main mechanism of ARDS is uncontrolled systemic inflammatory response and cytokine storm following release of proinflammatory cytokines (such as interferons (IFN), interleukines (IL), tumor necrosis factor (TNF)-α) and chemokines.<sup>2-3</sup>
So, some Chinese researchers proposed or used anti-inflammatory agents in the treatment regimen of patients with COVID-19.<sup>3-4</sup>
.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32267560</PMID>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>08</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-9114</ISSN>
<JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year>
<Month>Apr</Month>
<Day>08</Day>
</PubDate>
</JournalIssue>
<Title>Pharmacotherapy</Title>
<ISOAbbreviation>Pharmacotherapy</ISOAbbreviation>
</Journal>
<ArticleTitle>Considerations for statin therapy in patients with COVID-19.</ArticleTitle>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/phar.2397</ELocationID>
<Abstract><AbstractText>Current coronavirus pandemic named coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the third coronavirus outbreak during the current century after severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses.<sup>1</sup>
Acute respiratory distress syndrome (ARDS) is an immunopathologic event and main cause of death following COVID-19. The main mechanism of ARDS is uncontrolled systemic inflammatory response and cytokine storm following release of proinflammatory cytokines (such as interferons (IFN), interleukines (IL), tumor necrosis factor (TNF)-α) and chemokines.<sup>2-3</sup>
So, some Chinese researchers proposed or used anti-inflammatory agents in the treatment regimen of patients with COVID-19.<sup>3-4</sup>
.</AbstractText>
<CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dashti-Khavidaki</LastName>
<ForeName>Simin</ForeName>
<Initials>S</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0003-2004-7845</Identifier>
<AffiliationInfo><Affiliation>Professor of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Khalili</LastName>
<ForeName>Hossein</ForeName>
<Initials>H</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-1590-6396</Identifier>
<AffiliationInfo><Affiliation>Professor of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Pharmacotherapy</MedlineTA>
<NlmUniqueID>8111305</NlmUniqueID>
<ISSNLinking>0277-0008</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Coronavirus infection</Keyword>
<Keyword MajorTopicYN="N">HMG-CoA reductase inhibitor</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV</Keyword>
<Keyword MajorTopicYN="N">Statin</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32267560</ArticleId>
<ArticleId IdType="doi">10.1002/phar.2397</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000066 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000066 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:32267560 |texte= Considerations for statin therapy in patients with COVID-19. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:32267560" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
This area was generated with Dilib version V0.6.33. |